Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565638 · ClinicalTrials.gov registry record · NA
PROFAST Intervention in Precursor Multiple Myeloma
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT05565638 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 23 participants.
The verdict
NCT05565638, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering waldenstrom macroglobulinemia (SWM). The purpose of this study is to understand if fasting for a prolonged period of time during the nighttime hours is a strategy to prevent overweight and obese individuals from developing blood cancer. Participants will be randomized into the following two groups: * Group A: PROFAST intervention for 4 months * Group B: Healthy Lifestyle Control group for 4 months
Interventions
- BEHAVIORAL Prolonged Fasting Intervention
- BEHAVIORAL EDUCATION CONTROL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2025-08-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05565638
The ClinicalTrials.gov registry entry for NCT05565638 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prolonged Fasting Intervention is the first listed.
NCT05565638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05565638 about?
NCT05565638 is a clinical study titled "PROFAST Intervention in Precursor Multiple Myeloma". This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering waldenstrom macroglobulinemia (SWM). The purpose of this s...
What is the current status of trial NCT05565638?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2023-03-06. Estimated completion is 2025-08-04.
What interventions are being tested in trial NCT05565638?
The interventions under investigation include: Prolonged Fasting Intervention (BEHAVIORAL), EDUCATION CONTROL (BEHAVIORAL).
Who is sponsoring clinical trial NCT05565638?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.